Molecules That Inhibit Efflux Pumps in Multi-Drug Resistant Bacteria and Uses Thereof
US-2016361292-A1 · Dec 15, 2016 · US
Method of inhibiting gram-negative bacterial quorum signalling molecules using the macrocycle pillar[5]arene
US12433855B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12433855-B2 |
| Application number | US-201917283471-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 8, 2019 |
| Priority date | Oct 8, 2018 |
| Publication date | Oct 7, 2025 |
| Grant date | Oct 7, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to macrocyclic cavity containing compounds and uses thereof in inhibiting a microbial signalling molecule or in reducing the amount of a microbial signalling molecule in a subject. The invention also relates to methods for inhibiting a microbial signalling molecule or for reducing the amount of a microbial signalling molecule in a subject by contacting a macrocyclic cavity-containing compound with said subject.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method to inhibit a microbial quorum signalling molecule or to reduce the amount of a microbial quorum signalling molecule produced by a Gram-negative bacteria in a subject, by binding the microbial quorum signaling molecule selected from homoserine lactones (HSLs) or N-acyl homoserine lactones (AHLs) by non-covalent host-guest bonding by a macrocyclic cavity-containing compound, wherein the method comprises contacting the macrocyclic, cavity-containing compound selected from pillar[5]arenes and/or salts thereof with said subject. 2. The method according to claim 1 , wherein the Gram-negative bacteria comprises planktonic microbes. 3. A method to prevent or treat a microbial quorum signalling molecule dependent and/or mediated infection in a subject or a medium, which infection is caused by a Gram-negative bacteria by binding the microbial quorum signaling molecule selected from homoserine lactones (HSLs) or N-acyl homoserine lactones (AHLs) by non-covalent host-guest bonding by a macrocyclic cavity-containing compound, wherein the method comprises contacting the macrocyclic cavity-containing compound selected from pillar[5]arenes and/or salts thereof with said subject or medium. 4. The method according to claim 3 , wherein the infection is an acute infection or the infection is caused by planktonic microbes. 5. A method to reduce or abolish virulence in a Gram-negative bacteria by non-covalent host-guest bonding between a macrocyclic cavity-containing compound and a microbial quorum signaling molecule selected from homoserine lactones (HSLs) or N-acyl homoserine lactones (AHLs) produced by a Gram-negative bacteria, wherein the macrocyclic cavity-containing compound is selected from pillar[5]arenes and/or salts thereof. 6. The method according to claim 5 , wherein the Gram-negative bacteria comprises planktonic microbes.
Assignees
Inventors
Classifications
Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K31/16; peroxy acids A61K31/327) · CPC title
- A61K31/724Primary
Cyclodextrins · CPC title
condensed with other heterocyclic ring systems, e.g. biotin, sorbinil · CPC title
having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel · CPC title
Antibacterial agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12433855B2 cover?
- This invention relates to macrocyclic cavity containing compounds and uses thereof in inhibiting a microbial signalling molecule or in reducing the amount of a microbial signalling molecule in a subject. The invention also relates to methods for inhibiting a microbial signalling molecule or for reducing the amount of a microbial signalling molecule in a subject by contacting a macrocyclic cavit…
- Who is the assignee on this patent?
- Aalto Univ Foundation Sr
- What technology area does this patent fall under?
- Primary CPC classification A61K31/724. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).